The Underside Of eFFECTOR Therapeutics Inc (EFTR) Stock Is A Little Uncertain

Stifel lowered the price target for the eFFECTOR Therapeutics Inc (NASDAQ:EFTR) stock from “a Buy” to “a Hold”. The rating was released on January 25, 2022, according to finviz. The research report from Credit Suisse has initiated the stock to Outperform, with a price target set at $20. The stock was initiated by Mizuho, who […]